Enhancing islet engraftment with rosiglitazone

Area of Science:

• Endocrinology
• Immunology
• Transplantation Biology

Background:

• Islet transplantation is a potential therapy for type 1 diabetes.
• Improving islet graft survival and function remains a significant challenge.

Purpose of the Study:

• To investigate the effect of rosiglitazone, a peroxisome proliferator-activated receptor agonist, on islet engraftment and function.
• To determine if rosiglitazone administration influences glycemic control and graft insulin content in diabetic mice.

Main Methods:

• Streptozotocin-induced diabetic C57BL/6 mice received daily rosiglitazone (2.4 mg/kg) for 9 or 31 days before islet transplantation.
• Mice received either 75 or 150 syngeneic islets.
• In vitro studies assessed islet function and immune cell responses.

Main Results:

• Short-term rosiglitazone treatment (9 and 31 days) significantly increased the rate of normoglycemia post-transplantation compared to controls.
• Islet grafts in rosiglitazone-treated mice showed higher insulin content.
• In vitro, rosiglitazone inhibited pro-inflammatory cytokine secretion (IL-1β, IFN-γ) but did not directly affect islet insulin secretion or content.

Conclusions:

• Short-term administration of rosiglitazone enhances islet engraftment and improves glycemic control in diabetic mice.
• The beneficial effects may be partly mediated by immunomodulatory actions rather than direct effects on islet function.
• Rosiglitazone shows promise as an adjunct therapy to improve islet transplantation outcomes.